SAN ANTONIO – StemBioSys Inc. announced today that it has licensed additional technology from UT Health™ San Antonio that expands the company’s intellectual property portfolio aimed at enabling the expansion of adult stem cells for therapeutic use.
To date StemBioSys has converted three pending patents originally licensed from UT Health™San Antonio into eight issued and a dozen pending patent applications. The latest technology is aimed at the enrichment and amplification of highly potent stem cells from elderly individuals.
StemBioSys President & CEO, Bob Hutchens said, “This patent is an important application of our existing High Performance Micro Environment (HPME®) technology. The patent provides a potential way for elderly patients to benefit from stem cell treatments for a variety of conditions. We are very excited about bringing this ‘know how’ into StemBioSys.”
“As we age the numbers of healthy and potent stem cells in our body is diminished,” he said. “This new technology has the potential to identify and isolate the remaining stem cells that are still potent and expand their numbers to clinically relevant levels allowing for an autologous stem cell transplant equivalent to what you might expect in a much younger individual.”
Robert Langer, David H. Koch Institute Professor at MIT and a member of the StemBioSys Board of Directors said, “Recent studies have indicated that the local environment in tissues from elderly individuals may not be conducive to maintaining the regenerative potential of stem cells. This technology could potentially address that problem, leading to new alternatives for stem cell transplants for the elderly population.”
John Gebhard, Assistant Vice President of the Office of Technology Commercialization at UT Health™ San Antonio, added, “We are excited to see the further development of this gap-filling technology for the elderly population through StemBioSys. The company’s ability to translate UT Health™ San Antonio innovations to impact human health has been truly impressive.”
Hutchens said StemBioSys has also hired one of the primary inventors of this technology, Travis Block, PhD. Dr. Block has just recently finished his Ph.D. dissertation research which focused on this technology and matriculated out of the company co-founders laboratory (Dr. Xiao-Dong Chen, MD, PhD, Department of Comprehensive Dentistry, University of Texas Health San Antonio, San Antonio, TX).
About StemBioSys Inc.
StemBioSys, Inc., a privately held, San Antonio-based biomedical company, manufactures and develops innovative, advanced stem cell technologies to meet the promise of regenerative medicine in a surging global market. Its patented and proprietary technology platforms – licensed from the University of Texas System – overcome key obstacles to creating clinically useful stem cell therapies.
About UT Health™ San Antonio
The University of Texas Health Science Center at San Antonio, with missions of teaching, research and healing, is one of the country’s leading health sciences universities. Its schools of medicine, nursing, dentistry, health professions and graduate biomedical sciences have more than 33,000 alumni who are advancing their fields throughout the world. With four campuses in San Antonio and Laredo, the university has a FY 2017 revenue operating budget of $806.6 million and is the primary driver of its community’s $37 billion biomedical and health care industry. For more information on the many ways “We make lives better®,” visit www.uthscsa.edu.